Abcellera Biologics Inc. Stock Price, News & Analysis

AbCellera (Nasdaq: ABCL) reported Q2 2025 financial results and announced a significant milestone with the initiation of dosing in a Phase 1 clinical trial for ABCL635, targeting vasomotor symptoms in menopause. The company reported revenue of $17.1M (up from $7.3M in Q2 2024) and a net loss of $34.7M.

Key developments include authorization for Phase 1 trials of both ABCL635 and ABCL575, advancing ABCL688 into IND-enabling studies, and reaching 102 partner-initiated programs. The company maintains strong liquidity with $753M available, including $580M in cash and $173M in government funding.

AbCellera (NASDAQ: ABCL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host an earnings conference call at 2:00 PM PT / 5:00 PM ET on the same day. Investors can access the live audio webcast through AbCellera's Investor Relations website, where a replay will also be available after the call.

AbCellera (ABCL) has received authorization from Health Canada through a No Objection Letter (NOL) for its Clinical Trial Application of ABCL575, a novel antibody treatment targeting OX40 ligand. ABCL575 is being developed as a potential treatment for moderate-to-severe atopic dermatitis, with possible applications in other inflammatory and autoimmune conditions. The Phase 1 clinical trial, scheduled to begin in Q3 2025, will assess the safety and pharmacokinetics of ABCL575 when administered subcutaneously in healthy participants. The investigational antibody is designed as an Fc-silenced, half-life extended medicine.

AbCellera (ABCL) has received authorization from Health Canada to proceed with Phase 1 clinical trials for ABCL635, their investigational antibody treatment targeting neurokinin 3 receptor (NK3R). The drug is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, in menopausal women.

The Phase 1 trial, scheduled to begin in Q3 2025, will evaluate ABCL635's safety, pharmacokinetics, and pharmacodynamics in both healthy participants and postmenopausal women experiencing moderate-to-severe VMS. The company aims to provide a long-acting treatment option for millions of women affected by these disruptive menopausal symptoms.

The U.S. Court of Appeals for the Federal Circuit (CAFC) has affirmed the validity of AbCellera's (NASDAQ: ABCL) U.S. Patent No. 10,087,408 through a Rule 36 Order. The patent covers microfluidic devices and their use in culturing and selectively recovering cells. This ruling rejects Bruker Cellular Analysis's (formerly Berkeley Lights) challenge, which alleged invalidity based on anticipation and obviousness. The U.S. Patent Trial and Appeal Board (PTAB) had previously rejected Bruker's arguments. This patent is part of an ongoing multi-patent infringement litigation between AbCellera and Bruker in the U.S. District Court for the Northern District of California.

AbCellera (ABCL) presented preclinical data for ABCL575, a novel anti-OX40L monoclonal antibody developed for treating moderate-to-severe atopic dermatitis, at the 2025 SID Annual Meeting. The drug demonstrated potent inhibition of inflammatory pathways and showed promising characteristics including:

- Equivalent functional activity to leading clinical benchmarks - Modified Fc domain supporting Fc-silencing and half-life extension - Predicted human half-life exceeding 60 days - Positive nonclinical safety profile - Favorable stability at high concentration

The company plans to advance ABCL575 to clinical trials within 2025, positioning it as a potential best-in-class treatment for atopic dermatitis with less frequent dosing requirements.

AbCellera (ABCL) reported its Q1 2025 financial results, highlighting the introduction of ABCL635, a potential first-in-class antibody for non-hormonal treatment of menopausal hot flashes. The company posted revenue of $4.2 million, down from $10.0 million in Q1 2024, and a net loss of $45.6 million ($0.15 per share) compared to $40.6 million loss in Q1 2024.

The company reached 97 partner-initiated program starts with downstreams (up 8% YoY) and increased its molecules in the clinic to 16 (up 23% YoY). AbCellera maintains strong liquidity with $810 million available, including $633 million in cash and equivalents and $178 million in non-dilutive government funding. The company plans to initiate Phase 1 clinical trials for both ABCL635 and ABCL575 in H2 2025.

AbCellera has unveiled promising preclinical data for its PSMA x CD3 T-cell engagers (TCEs) at the AACR Annual Meeting 2025. The research focuses on potential treatments for metastatic castration-resistant prostate cancer (mCRPC).

Key findings include:

• Potent tumor-cell killing ability, with one molecule showing ~10x higher EC50 than benchmark
• Sustained activity across four rounds of serial T-cell killing
• Significant tumor growth inhibition in xenograft mouse models
• Enhanced potency potential when combined with costimulatory PSMA x CD28 bispecifics

This marks the first demonstration of AbCellera's novel CD3-binders generating molecules with strong anti-tumor efficacy in vivo. The company's TCE platform strategy combines diverse CD3 and tumor-binding antibodies to develop optimized therapeutic candidates.

AbCellera (Nasdaq: ABCL) has announced its upcoming participation in two major investor conferences. The company will attend the Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6, and the Goldman Sachs 46th Annual Global Healthcare conference taking place June 9-11. Interested parties can find more details on AbCellera's Investor Relations website.